Topics in this section

Hepatitis and HIV: latest news

Hepatitis and HIV resources

  • Other tests

    Blood pressure is the force that the beating heart causes in the arteries, veins, and blood vessels that carry blood around the body. Blood pressure is measured...

    From: Booklets

    Information level Level 2
  • How hepatitis C is passed on during sex

    Hepatitis C can be passed on during sex that could lead to contact with semen, rectal mucus or blood.Many gay men with HIV have picked...

    From: The basics

    Information level Level 1
  • The liver

    The liver plays an important role in how the body processes anti-HIV drugs.Hepatitis means inflammation of the liver and is relatively common in people with...

    From: Factsheets

    Information level Level 2
  • Hepatitis and other liver disease

    The liver has many important functions in the body. For people with HIV, it plays a vital role in processing the drugs used to treat HIV. Some...

    From: Booklets

    Information level Level 2
  • Hepatitis B

    The majority of people with hepatitis B do not have any symptoms.It is recommended that people living with HIV are tested and vaccinated for hepatitis...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    A blood test for antibodies will show if you have been exposed to hepatitis C.HIV treatment has particular benefits for people with HIV and hepatitis...

    From: Factsheets

    Information level Level 2
  • Liver function tests

    People living with HIV should have regular blood tests to monitor liver function.The liver plays an important role in processing drugs used to treat HIV...

    From: Factsheets

    Information level Level 2
  • Managing advanced liver disease

    Over years or decades, chronic hepatitis B or C can cause serious liver disease including advanced fibrosis, cirrhosis or liver cancer (hepatocellular cancer). As scar tissue or tumours...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • HIV & hepatitis

    This booklet gives information for people with HIV who also have hepatitis A, hepatitis B or hepatitis C....

    From: Booklets

    Information level Level 2
  • HIV and hepatitis co-infection

    Hepatitis is a viral infection that affects your liver. Some types – hepatitis B and C – can cause long-term, serious health problems. Many people with HIV...

    From: Booklets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1
  • How hepatitis C is passed on

    When the blood of a person who has hepatitis C enters the bloodstream of another person, that person could get hepatitis C.Tiny and unseen traces...

    From: The basics

    Information level Level 1

Hepatitis and HIV features

Hepatitis and HIV in your own words

Hepatitis and HIV news from aidsmap

More news

Hepatitis and HIV news selected from other sources

  • Eliminating viral hepatitis: time to match visions with action

    Fundamentally, the tools needed to move towards elimination targets already exist—an effective vaccine for hepatitis B and a curative treatment for hepatitis C. What is needed now more than anything else is the political will to scale up prevention, diagnosis, and treatment programmes.

    10 November 2017 | The Lancet (editorial)
  • 8 things to know ahead of the World Hepatitis Summit

    Devex spoke with Gottfried Hirnschall and Marc Bulterys of the World Health Organization about the gaps, outstanding challenges, and ongoing work toward elimination. Here’s what you can expect from the three-day meeting.

    02 November 2017 | Devex
  • Hep C: An end in sight?

    Despite its prevalence, hepatitis C has long been under-prioritised by health services. But could new drugs and a new commitment from the NHS mean we may finally see this killer condition eradicated?

    05 October 2017 | Drink & Drug News
  • Gay men with hepatitis C are suffering stigma not seen since the HIV/AIDS crisis

    It seems that hepatitis C has taken on the stigma and fear that HIV once carried. But as an illness that also disproportionately affects gay and bisexual men, it seems that awareness and education remains woefully low.

    25 September 2017 | Attitude
  • Viral Hepatitis kills more people than HIV, malaria or tuberculosis

    According to the Global Burden of Disease study released today, deaths caused by viral hepatitis have surpassed all chronic infectious diseases including HIV/AIDS, malaria and tuberculosis.

    18 September 2017 | World Hepatitis Alliance
  • J&J unit ends hepatitis C drug development in crowded market

    Janssen Sciences Ireland UC, a unit of Johnson & Johnson, said it would discontinue further development of its hepatitis C research, citing increased availability of a number of effective hepatitis C therapies.

    11 September 2017 | Reuters
  • From chronic to cured: could Australia be the first country in the world to eliminate hep C?

    Australia is on track to eliminate hepatitis C by 2026, a new report released by the Kirby Institute on World Hepatitis Day shows.

    28 July 2017 | Kirby Institute
  • ECDC estimate: Around 9 million Europeans are affected by chronic hepatitis B or C

    An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million with chronic hepatitis C infection. But large numbers of them are not aware of their infection as they have not yet been diagnosed. On of World Hepatitis Day, ECDC Director Andrea Ammon highlights the need for Europe to scale-up coverage of testing, prevention interventions and linkage to suitable treatment services to achieve the target of eliminating viral hepatitis by 2030.

    27 July 2017 | Eurekalert Inf Dis
  • WHO prequalifies first generic hepatitis C medicine and first HIV self-test

    WHO today prequalified the first generic version of sofosbuvir, a critical medicine for the treatment of hepatitis C. The development could expand access to treatment by increasing the number of quality-assured generic medicines on the market. Sofosbuvir, 400 mg tablet, is manufactured by Mylan Laboratories Ltd., India.

    22 July 2017 | World Health Organization
  • Targeting MSM with HIV: Treatment as Prevention in the Netherlands

    As part of Dutch HIV guidelines, all individuals with HIV are screened for hepatitis C. Anne Boerekamps, MD, of Erasmus University Medical Center in Rotterdam, the Netherlands, spoke with HCV Next about the Dutch approach, the relevant data, and other topics associated with screening and treating MSM.

    18 July 2017 | Healio Hepatology
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.